MYGN · Myriad Genetics, Inc.

Current Thesis

Myriad Genetics' rebound prices a commercial turnaround; the next quarterly report must show an end to revenue-per-test declines while the market holds the reclaimed $3.67 level. This is a recovery hypothesis, not an established operating improvement. Its price invalidation is a weekly close below $3.67, the former resistance identified in the 2026-09-05 published assessment.

The material development since that assessment is commercial leadership: Vishal Sikri became executive vice president, commercial, on 2026-09-16, replacing Brian Donnelly as the senior commercial executive. The filing establishes a personnel change; it supplies no evidence that collections have improved. September 16 Form 8-K.

The original earnings-backed diagnostics-pivot narrative is dead — the 2026-07-30 revenue-guidance reduction and suspension of the profitability outlook broke its financial premise. The September rebound therefore requires fresh operating confirmation before that assessment changes. July 30 results.

Bullish and bearish views on Myriad Genetics, Inc.

The model's bull view on Myriad Genetics, Inc. (MYGN), in brief: The former ceiling is reclaimed. The adjusted market close of $3.89 on 2026-09-18 exceeded the $3.67 resistance documented on 2026-09-05. This supports a provisional recovery interpretation, invalidated by a weekly close below $3.67. Testing demand has not collapsed. The… The bear view: Realized revenue remains the problem. On 2026-07-30, Myriad reported second-quarter revenue of $190.7 million, down 11% year over year, and revenue per test down 9%. Quarterly results. The financial reset remains substantial. The 2026-07-30 release reduced full-year revenue… Both cases follow in full.

Bull Case

• The former ceiling is reclaimed. The adjusted market close of $3.89 on 2026-09-18 exceeded the $3.67 resistance documented on 2026-09-05. This supports a provisional recovery interpretation, invalidated by a weekly close below $3.67.
• Testing demand has not collapsed. The 2026-07-30 results reported second-quarter total test volume down 1% year over year and hereditary-cancer volume up 8%. Quarterly results.
• Product expansion is already delivered. The 2026-07-30 release described Precise molecular residual disease (MRD) availability as expanded to breast, colorectal and renal cancers. Product availability alone does not establish reimbursement or revenue contribution. Company disclosure.

Bear Case

• Realized revenue remains the problem. On 2026-07-30, Myriad reported second-quarter revenue of $190.7 million, down 11% year over year, and revenue per test down 9%. Quarterly results.
• The financial reset remains substantial. The 2026-07-30 release reduced full-year revenue guidance to $770–790 million and suspended adjusted earnings before interest, taxes, depreciation and amortization guidance. Guidance disclosure.
• Analyst support has not strengthened. UBS retained a Neutral rating on 2026-09-09, according to MarketBeat's dated analyst record. That supplies no independent endorsement of an operating recovery. Analyst history.

Setup & Price Structure

The 2026-09-18 adjusted close was $3.89, with a three-month price decline of 13.6% and a 14-period relative strength index (RSI) of 75.2. These observations describe strong recent momentum inside a still-negative medium-term price record. They do not establish the cause of the rebound.

The $3.67 former ceiling is the research invalidation level because the latest close has reclaimed it. One supplied close above that level is insufficient to establish durable support. The 2026-08-14 low of $3.03 remains an older market reference, rather than evidence that the present recovery has already succeeded.

The RSI reading measures momentum, not ownership concentration. No dated short-interest or retail-flow series supports a crowding conclusion here, and the available observations are too limited to identify expanding participation.

Catalyst Calendar (next 30 days)

• 2026-09-21 — Commercial transition milestone. The September 16 filing says Donnelly is expected to remain a non-executive employee through this date to assist the handover. This is an administrative milestone, without a scheduled financial update. Form 8-K.
• 2026-09-19 through 2026-10-19 — No confirmed financial catalyst. The company events calendar reviewed on 2026-09-19 lists the elapsed September 10 conference but no subsequent earnings date within this window. The next quarterly report remains the operating test; its date is unconfirmed. Company events calendar.

The earlier September 30 launch checkpoint is obsolete: the July 30 release already described the MRD expansion as completed. Its passage cannot fairly be scored as a missed launch. Company results.

What Would Change Our Mind

Failure of the reclaimed September resistance would end the current price-recovery hypothesis: a weekly close below $3.67 would return the shares beneath the ceiling documented on 2026-09-05. This condition applies to the new recovery hypothesis; it does not revive the failed July structure.

For this thesis to play out before that breach, the next quarterly report must show revenue per test no longer declining year over year and retain the reset annual revenue guidance. Continued deterioration or another reduction would contradict commercial stabilization. Until that test, the evidence supports low conviction despite the September price improvement.

Correlation Notes

This is a single-name recovery hypothesis. The September 16 commercial-leadership change is company-specific, while the September 18 momentum reading supplies no evidence of a broader diagnostics-sector move. No paired return sample establishes correlation with diagnostic peers or biotechnology indices, so no group-driven confirmation is claimed.